Semaglutide research guide — GLP-1 receptor mechanism, study context, reconstitution and handling for the research peptide. For laboratory research use only.
Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1) with modifications that extend its biological half-life. It is a 31-amino acid peptide with a molecular weight of approximately 4113.58 g/mol and CAS number 910463-68-2. The peptide incorporates a C-18 fatty di-acid chain attached via a linker to Lys26, enabling strong albumin binding that significantly extends its duration of action compared to native GLP-1.
Semaglutide contains three key modifications relative to native GLP-1: (1) An Aib (alpha-aminoisobutyric acid) substitution at position 8, providing resistance to DPP-4 enzymatic cleavage. (2) An Arg substitution at position 34, preventing fatty acid acylation at the wrong site. (3) A C-18 fatty di-acid acylation at Lys26 via a mini-PEG linker, enabling non-covalent albumin binding. These modifications collectively extend the half-life from approximately 2 minutes (native GLP-1) to approximately 7 days.
As a selective GLP-1 receptor agonist, semaglutide binds to and activates the GLP-1 receptor (GLP-1R), a G-protein coupled receptor expressed on pancreatic beta cells, central nervous system neurons, and gastrointestinal tract cells. Receptor activation triggers cAMP-dependent signalling cascades that influence insulin secretion, glucagon suppression, gastric emptying, and central appetite regulation. Unlike dual agonists such as tirzepatide, semaglutide does not activate the GIP receptor.
GLP-1 receptor signalling pathway studies. Incretin biology and beta-cell function research. Appetite and satiety neuroscience investigations. Comparative agonist studies (single vs dual vs triple agonism). Receptor binding affinity and selectivity assays. Metabolic pathway and glucose homeostasis research. Cardiovascular effects of GLP-1 receptor activation.
Semaglutide vs Liraglutide: semaglutide has a longer half-life (7 days vs 13 hours) due to its C-18 fatty di-acid chain versus liraglutide's C-16 palmitoyl chain. Semaglutide vs Tirzepatide: tirzepatide additionally targets GIP receptors, enabling study of dual incretin pathway activation. Semaglutide vs Retatrutide: retatrutide is a triple agonist (GLP-1 + GIP + glucagon), providing the broadest receptor coverage. Each provides distinct tools for studying incretin biology at different levels of complexity.
Molecular Weight: 4113.58 g/mol. CAS Number: 910463-68-2. Purity: 99%+ (HPLC verified). Form: Lyophilised white powder. Solubility: Soluble in bacteriostatic water at neutral pH. Storage: -20°C (lyophilised), 2-8°C (reconstituted, use within 4 weeks).
Research-grade compounds referenced in this guide, supplied with full Certificates of Analysis.
All products sold by Neovia Peptides are strictly for in-vitro research and laboratory use only. Not intended for human or veterinary use, food additives, drugs, or cosmetics. By purchasing from this website, you agree that you understand and accept these terms.
